SynthesisJournal of the American Heart Association2025
Dedicated Versus Conventional Devices in Patients With Pure Native Aortic Regurgitation: A Systematic Review and Meta-Analysis.
Synthesis in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcatheter Aortic Valve Migration and Embolization During Transcatheter Aortic Valve Replacement: A Contemporary Management Review With a Practical Bailout Algorithm.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical aortic valve replacement is the gold standard for treating pure native aortic regurgitation. However, many patients have unacceptable surgical risk. Increasing evidence supports the use of transcatheter aortic valve replacement in this subset. This metanalysis aims to evaluate transcatheter aortic valve replacement efficacy in pure native aortic regurgitation.
methodsWe systematically searched MEDLINE/PubMed, Embase, the Cochrane Database, Google Scholar, ClinicalTrials.gov, and major cardiology conference abstracts from inception to April 1, 2024, and included 19 observational studies with ≥20 patients with pure native aortic regurgitation undergoing transcatheter aortic valve replacement. The primary end point was 30-day all-cause mortality; secondary end points were device success, valve migration, and 1-year all-cause mortality. Pooled estimates were calculated using random-effects meta-analysis. Risk of bias was assessed using the Newcastle-Ottawa Scale and publication bias with funnel plots and Egger's test. The study protocol was registered in International Prospective Register of Systematic Reviews (CRD42024534117).
resultsThe pooled 30-day mortality was 8.7% (95% CI, 5.8%-10.7%), and decreased from first (16.9% [95% CI, 13.2%-18.9%]) to second generation (7.2% [95% CI, 6.1%-9.2%]) and dedicated devices (4.7% [95% CI, 1.8%-8.9%;
conclusionsAlthough the observational design, lack of patient-level data, device heterogeneity, and potential publication bias limit definitive conclusions, transcatheter aortic valve replacement using dedicated devices may be considered a safe and effective therapeutic option for patients with pure native aortic regurgitation and unacceptable risk for surgery. REGISTRATION: URL: https://www.crd.york.ac.uk/prospero/; Unique identifier: CRD42024534117.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.